Big Pharma firms, NIH to join up to study major diseases

Ten major pharmaceuticals companies are getting together with the National Institutes of Health and other organizations in a five-year partnership that will look to understand the science behind Alzheimer's, Type 2 diabetes, rheumatoid arthritis and lupus.

In an unusual move, the normally secretive participants will share scientists, tissue, blood samples and data, with the aim being to identify targets for new drugs.

The firms involved include Bristol-Myers Squibb (BMY), Johnson & Johnson (JNJ), GlaxoSmithKline (GSK), Takeda (TKPHF) and Sanofi (SNY).

Those that haven't joined include Amgen (AMGN), Roche (RHHBY) and AstraZeneca (AZN).

From other sites
Comments (4)
  • theo_rhetoric
    , contributor
    Comments (260) | Send Message
    Collaboration has produced some of the greatest leaps in solutions. This is the kind of leadership I desire from my government.
    4 Feb 2014, 08:45 AM Reply Like
  • RWMostow
    , contributor
    Comments (1691) | Send Message
    I do not see cancer on the list. What happened?


    4 Feb 2014, 09:07 AM Reply Like
  • jameswparker
    , contributor
    Comments (13) | Send Message
    No major progress has been made in the treatment of these 4 diseases. Sharing & collaboration could move the pharmaceutical companies forward by decades in less than 5 yrs.
    4 Feb 2014, 11:16 AM Reply Like
  • BlueOkie
    , contributor
    Comments (10638) | Send Message
    Since when has the gov't got involved in something besides defense and improved upon it. If they find a cure, who develops the drug? You still have FDA. What exactly does NIH bring to the party.
    4 Feb 2014, 12:21 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs